Breast cancer is the most common cancer affecting women worldwide. Despite tremendous advances in screening, diagnosis, and treatment, the causes of this disease remain elusive and complex. Proteomics is a rapidly developing field that can explore the heterogeneity of breast cancer and supplement the wealth of information gained from genomics.
Methods
This article serves as an overview of the application of matrix-assisted laser desorption/ionization source with a time-of-flight (MALDI-TOF) proteomic techniques as applied to breast cancer. Examples of the clinical applicability of MALDI-TOF mass spectrometry are provided but represent only a fraction of the potential uses yet to be discovered. In addition, a brief summary of the bioinformatics issues that surround proteomics is included.
Results
Mass spectrometry has provided new proteomic approaches to unravel the complexities of clinical specimens relevant to breast cancer diagnostics. In particular, MALDI-TOF mass spectrometry analysis has been used to differentiate cancer profiles from benign profiles in samples from sera, plasma, tissue, nipple fluid, and ductal lavage. Some discriminating proteins have subsequently been identified.
Conclusions
Mass spectrometry applications to breast cancer diagnostics continue to be developed but are evolving faster than bioinformatics/statistical analysis can adapt. The future of these techniques in terms of clinical investigation is limitless, but in terms of general applicability, these applications are currently cost-prohibitive.
References
1.
National Breast and Cervical Cancer Early Detection Program: Screening Program Data. Department of Health and Human Services. Centers for DiseaseControl and Prevention. Available at http://www.cdc.gov/cancer/nbccedp/data/. Accessed on July 26, 2007.
2.
FisherB., AndersonS., RedmondC.K.. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.N Engl J Med.1995; 333: 1456–1461.
3.
KelleyM.C., HansenN., McMastersK.M.. Lymphatic mapping and sentinel lymphadenectomy for breast cancer.Am J Surg.2004; 188: 49–61.
4.
AltundagK., EstevaF.J., ArunB.. Monoclonal antibody-based targeted therapy in breast cancer.Curr Med Chem Anticancer Agents.2005; 5: 99–106.
5.
ChenS., IversenE.S., FriebelT.. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.J Clin Oncol.2006; 24: 863–871.
6.
AebersoldR., MannM.. Mass spectrometry-based proteomics.Nature.2003; 422: 198–207.
7.
BertucciF., BirnbaumD., GoncalvesA.. Proteomics of breast cancer: principles and potential clinical applications.Mol Cell Proteomics.2006; 5: 1772–1786. Epub 2006 May 29.
8.
WrightG.L.. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.Expert Rev Mol Diagn.2002; 2: 549–563.
9.
AdamB.L., QuY., DavisJ.W.. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.Cancer Res.2002; 62: 3609–3614.
10.
SemmesO.J., FengZ., AdamB.L.. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. assessment of platform reproducibility.Clin Chem.2005; 51: 102–112.
11.
LiJ., ZhangZ., RosenzweigJ.. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer.Clin Chem.2002; 48: 1296–1304.
12.
VlahouA., LarongaC., WilsonL.. A novel approach toward development of a rapid blood test for breast cancer.Clin Breast Cancer.2003; 4: 203–209.
13.
BeckerS., CazaresL.H., WatsonP.. Surfaced-enhanced laser desorption/ionization-time of flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer.Ann Surg Oncol.2004; 11: 907–914. Epub 2004 Sep 20.
14.
LarongaC., BeckerS., WatsonP.. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.Dis Markers.2003-2004; 19(4-5): 229–238.
15.
PusztaiL., GregoryB.W., BaggerlyK.A.. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.Cancer.2004; 100: 1814–1822.
16.
ShinS., FournierK., SchneiderH.. Racial disparities in protein profiles of breast cancer ductal epithelial cells/sera. Presented at the Society of Surgical Oncology 58th Annual Cancer Symposium. Atlanta, Georgia. March 3-6, 2005.
17.
FournierK., VlahouA., GregoryB.. Application of SELDI-TOF mass spectrometry to breast ductal lavage fluid. Presented at the American Association of Cancer Research 94th Annual Meeting. Washington, DC. July 11-14, 2003.
18.
FournierK., MendrinosS., RitchieJ.. Feasibility of protein evaluation of ductal lavage fluid for breast diseases. Presented at the 26th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas. December 3-6, 2003.
19.
PawlikT.M., HawkeD.H., LiuY.. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.BMC Cancer.2006; 6: 68.
20.
PawlikT.M., FritscheH., CoombsK.R.. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry.Breast Cancer Res Treat.2005; 89: 149–157.
21.
ShinS., CazaresL., SchneiderH.. Serum biomarkers to differentiate benign and malignant mammographic lesions.J Am Coll Surg.2007; 204: 1065–1071; discussion 1071-1073.
22.
de NooM.E., DeelderA., van der WerffM.. MALDI-TOF serum protein profiling for the detection of breast cancer.Onkologie.2006; 29: 501–506. Epub 2006 Oct 25.
HuangH.L., StasykT., MorandellS.. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/maldi-TOF/TOF and data validation by routine clinical assays.Electrophoresis.2006; 27: 1641–1650.
25.
UmarA., DaleboutJ.C., TimmermansA.M.. Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrixassisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry.Proteomics.2005; 5: 2680–2688.
26.
CornettD.S., MobleyJ.A., DiasE.C.. A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer.Mol Cell Proteomics.2006; 5: 1975–1983. Epub 2006 Jul 18.
27.
HilarioM., KalousisA., PellegriniC.. Processing and classification of protein mass spectra.Mass Spectrom Rev.2006; 25: 409–449.
28.
PetricoinE.F., ArdekaniA.M., HittB.A.. Use of proteomic patterns in serum to identify ovarian cancer.Lancet.2002; 359: 572–577.
29.
BaggerlyK.A., MorrisJ.S., CoombesK.R.. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments.Bioinformatics.2004; 20: 777–785. Epub 2004 Jan 29.
30.
MathelinC., CromerA., WendlingC.. Serum biomarkers for detection of breast cancer: a prospective study.Breast Cancer Res Treat.2006; 96: 83–90.
31.
HuY., ZhangS., YuJ.. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer.Breast.2005; 14: 250–255.
32.
MalyarenkoD.I., CookeW.E., AdamB.L.. Enhancement of sensitivity and resolution of surface-enhanced laser desorption/ionization time-offlight mass spectrometric records for serum peptides using time-series analysis techniques.Clin Chem.2005; 51: 65–74. Epub 2004 Nov 18.
33.
MalyarenkoD.I., CookeW.E., TracyE.R.. Resampling and decon-volution of linear time-of-flight records for enhanced protein profiling.Rapid Commun Mass Spectrom.2006; 20: 1670–1678.
34.
CoombesK.R., TsavachidisS., MorrisJ.S.. Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform.Proteomics.2005; 5: 4107–4117.
35.
DuP., KibbeW.A., LinS.M.. Improved peak detection in mass spectrum by incorporating continuous wavelet transform-based pattern matching.Bioinformatics.2006; 22: 2059–2065. Epub 2006 Jul 4.
36.
SaltzJ., OsterS., HastingsS.. caGrid: design and implementation of the core architecture of the cancer biomedical informatics grid.Bioinformatics.2006; 22: 1910–1916. Epub 2006 Jun 9.
